Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Multiple Oral Doses of SHR7280 in Healthy Subjects
NCT04554043Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR7280 in prostate cancer (PCa), endometriosis, Uterine Fibroids (UF) and 1 more (11 arms), sponsored by Hengrui. Primary endpoint: Number of Participants with Adverse events at 28 days. Started Sep 2020; status: completed.
02
Drugs
SHR7280
03
Conditions
prostate cancer (PCa)endometriosisUterine Fibroids (UF)infertility
Beyond the preview
Go deeper on NCT04554043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04554043.